Prediction of adverse outcomes in children with sickle cell disease

New England Journal of Medicine

Volumn 342, Issue 2, 2000, Pages 83-89

  Miller, Scott T ^a   Sleeper, Lynn A ^b   Pegelow, Charles H ^c   Enos, Laura E ^b   Wang, Winfred C ^d   Weiner, Steven J ^b   Wethers, Doris L ^e   Smith, Jeanne ^f   Kinney, Thomas R ^g  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b NEW ENGLAND RESEARCH INSTITUTES   (United States)

^c UNIVERSITY OF MIAMI   (United States)

^d ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^e ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

^f HARLEM HOSPITAL CENTER   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN;

ANEMIA; ARTICLE; BETA THALASSEMIA; DISEASE COURSE; HIGH RISK PATIENT; HUMAN; INFANT; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MODEL; PRIORITY JOURNAL; PROGNOSIS; SICKLE CELL ANEMIA; STROKE;

ANEMIA; ANEMIA, SICKLE CELL; BETA-THALASSEMIA; CEREBROVASCULAR ACCIDENT; COHORT STUDIES; EXTREMITIES; HUMANS; INFANT; INFLAMMATION; LEUKOCYTOSIS; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; PAIN; PROGNOSIS; RETROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 0034642592     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200001133420203     Document Type: Article

References (37)

1. Herrick JB. Peculiar elongated and sickle-shape red blood corpuscles in a case of severe anemia. Arch Intern Med 1910;6:517-21.
2. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med 1997;337:762-9.
3. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med 1994;330: 1639-44.
4. Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W. Mortality in children and adolescents with sickle cell disease. Pediatrics 1989; 84:500-8.
5. Reid CD, Charache S, Lubin B, eds. Management and therapy of sickle cell disease. 3rd ed. rev. Bethesda, Md.: National Heart, Lung, and Blood Institute, December 1995. (NIH publication no. 95-2117.)
6. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332: 1317-22.
7. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. N Engl J Med 1996;335:369-76.
8. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998;91:288-94.
9. Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. Blood 1994;84:643-9.
10. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease: rates and risk factors. N Engl J Med 1991;325:11-6.
11. Milner PF, Kraus AP, Sebes JI, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med 1991;325:1476-81.
12. Koshy M, Entsuah R, Koranda A, et al. Leg ulcers in patients with sickle cell disease. Blood 1989;74:1403-8.
13. Zarkowsky HS, Gallagher D, Gill FM, et al. Bacteremia in sickle hemoglobinopathies. J Pediatr 1986;109:579-85.
14. Bray GL, Muenz L, Makris N, Lessin LS. Assessing clinical severity in children with sickle cell disease: preliminary results from a cooperative study. Am J Pediatr Hematol Oncol 1994;16:50-4.
15. Gaston MH, Rosse WF. The Cooperative Study of Sickle Cell Disease: review of study design and objectives. Am J Pediatr Hematol Oncol 1982; 4:197-201.
16. Gaston M, Smith J, Gallagher D, et al. Recruitment in the Cooperative Study of Sickle Cell Disease (CSSCD). Control Clin Trials 1987;8:Suppl: 131S-140S.
17. Gill FM, Sleeper LA, Weiner SJ, et al. Clinical events in the first decade in a cohort of infants with sickle cell disease. Blood 1995;86:776-83.
18. Adams JG III. Clinical laboratory diagnosis. In: Embury SH, Hebbel RP, Mohandas N, Steinberg MH, eds. Sickle cell disease: basic principles and clinical practice. New York: Raven Press, 1994:457-68.
19. Wrightstone RN, Huisman TH. On the levels of hemoglobins F and A2 in sickle-cell anemia and some related disorders. Am J Clin Pathol 1974; 61:375-81.
20. Embury SH, Miller JA, Dozy AM, Kan YW, Chan V, Todd D. Two different molecular organizations account for the single-alpha-globin gene of the alpha-thalassemia-2 genotype. J Clin Invest 1980;66:1319-25.
21. 5-Gene-cluster haplotypes in sickle cell anemia: clinical and hematologic features. Hematol Oncol Clin North Am 1991;5:475-93.
22. West MS, Wethers D, Smith J, Steinberg M. Laboratory profile of sickle cell disease: a cross-sectional analysis. J Clin Epidemiol 1992;45:893-909.
23. Pearson HA, Gallagher D, Chilcote R, et al. Developmental pattern of splenic dysfunction in sickle cell disorders. Pediatrics 1985;76:392-7.
24. Moser FG, Miller ST, Bello JA, et al. The spectrum of brain MR abnormalities in sickle cell disease: a report from the Cooperative Study of Sickle Cell Disease. AJNR Am J Neuroradiol 1996;17:965-72.
25. Powars D, Weidman JA, Odom-Maryon T, Niland JC, Johnson C. Sickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine (Baltimore) 1988;67:66-76.
26. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34: 187-220.
27. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman & Hall, 1993:141-50.
28. Powars DR, Weiss JN, Chan LS, Schroeder WA. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia? Blood 1984;63:921-6.
29. Noguchi CT, Rodgers GP, Serjeant G, Schechter AN. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med 1988;318:96-9.
30. Pass KA. Newborn screening - implementing a system. In: Stern KS, Davis JG, eds. Newborn screening for sickle cell disease: issues and implications. New York: Council of Regional Networks for Genetic Services, Cornell University Medical College, March 1994:29-34.
31. Balkaran B, Char G, Morris JS, Thomas FW, Serjeant BE, Serjeant GR. Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr 1992;120:360-6.
32. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989;320: 365-76.
33. Bratt J, Palmblad J. Cytokine-induced neutrophil-mediated injury of human endothelial cells. J Immunol 1997;159:912-8.
34. Fadlon E, Vordermeier S, Pearson TC, et al. Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. Blood 1998;91:266-74.
35. Koshy M, Thomas C, Goodwin J. Vascular lesions in the central nervous system in sickle cell disease (neuropathology). J Assoc Acad Minor Phys 1990;1:71-8.
36. Lane PA, O'Connell JL, Lear JL, et al. Functional asplenia in hemoglobin SC disease. Blood 1995;85:2238-44.
37. 5-gene-cluster haplotypes as prognostic indicators of vital organ failure. Semin Hematol 1991;28:202-8.